Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
High efficacy of the LMB chemotherapy regimen in adult non HIV primary cerebral non-Hodgkin's lymphoma (Meeting abstract).
Proc Annu Meet Am Soc Clin Oncol; 13:A1275 1994. Unique Identifier : AIDSLINE ICDB/94601271 Blay JY; Bouhour D; Negrier S; Salles G; Philip T; Biron P; Centre L Berard, rue Laennec 69008, Lyon, France
Abstract:
Non HIV primary cerebral lymphoma (PCL) still have a poor prognosis with five years survival ranging between 5 and 30% in most series. Here, we report on a pilot study of the LMB regimen followed by radiotherapy in 20 patients (pts) with PCL. Pts received 2 courses of COPADEM (VCR 2 mg d1, MTX 3 g/m2 d1, CPM 500 mg/m2 d2-4, ADM 60 mg/m2 d2, IT MTX 15 mg d2,d6; prednisone 60 mg/m2 d1-d7) followed by 2 courses of CYM (MTX 3 g/m2 d1, Ara-C 100 mg/m2 continuous infusion d2-d6, IT Ara-C 15 mg d2,d6, prednisone 60 mg/m2 d1-d7) at 21 day intervals, followed by cranial radiotherapy (median whole cranial dose 40 Gy, range 24-50). The series included 8 females, 12 males, with a median age of 51 (range 14-73), median performance status: 2 (range 1-4). Respectively 8, 7 and 5 pts belonged to the good, intermediate and poor PCL prognostic groups (Br J Cancer 67:1136, 1993). One patient (age 61) died of septic shock during induction chemotherapy and one patient (age 58) died before the initiation of chemotherapy. One patient refused to continue the treatment after 3 courses of chemotherapy. One pt received only one of the 2 courses of COPADEM because of a brain abscess after stereotaxic biopsy of PCL. Among the 17 evaluable pts, 10 achieved partial response and 7 complete response on CT scan after chemotherapy and prior to radiation therapy. The projected 5-years overall survival is 57% for the whole group and 80% for pts of the good prognostic group (median follow-up 80 months). Median survival is 8 months for the 12 patients in the poor and intermediate prognostic groups with a projected 24 months survival of 40% (median follow up: 10 months). These results compare favorably with previously published protocols and this therapeutic program should be tested in a randomized study.
Keywords: Adolescence Adult Aged Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Brain Neoplasms/*DRUG THERAPY/MORTALITY/PATHOLOGY/RADIOTHERAPY Combined Modality Therapy Cranial Irradiation Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Cytarabine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Female Follow-Up Studies Human Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY/PATHOLOGY/ RADIOTHERAPY Male Methotrexate/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Middle Age Pilot Projects Survival Rate ABSTRACT 940830
M9480780
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
